The Era of Complete Genomics and Proteomics is Here
When faced with a difficult treatment decision, GPS Cancer® offers the most comprehensive molecular profile available – from DNA to RNA to protein – providing oncologists with unprecedented insights into the molecular signature of each patient’s cancer to inform personalized treatment strategies. This unique profile:
Includes whole genome sequencing of over 20,000 genes and 3 billion base pairs
Incorporates whole transcriptome sequencing of over 200,000 RNA transcripts
Leverages the power of quantitative proteomics by mass spectrometry
Compares a patient’s tumor genome to their normal genome
Based on the tumor’s “molecular fingerprint”, GPS Cancer offers insight into therapies that may have potential benefit, including FDA approved therapies and active clinical trials, and therapies to which the cancer may be resistant. GPS Cancer is performed in CAP-accredited, CLIA-certified labs.
Health Plan and Employer Brochure